Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.50 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.50 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 3/20 | 0.47 |
| ▸ | CTSB | P07858 | 2/20 | 0.45 |
| ▸ | AKR1B10 | O60218 | 2/20 | 0.44 |
| ▸ | AKR1B1 | P15121 | 2/20 | 0.44 |
| ▸ | CA12 | O43570 | 1/20 | 0.44 |
| ▸ | CA4 | P22748 | 1/20 | 0.44 |
| ▸ | CA6 | P23280 | 1/20 | 0.44 |
| ▸ | CA5A | P35218 | 1/20 | 0.44 |
| ▸ | CA7 | P43166 | 1/20 | 0.44 |
| ▸ | CA9 | Q16790 | 1/20 | 0.44 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.44 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7292873 | 0.92 | CYP1A2 (0.50) | ALDH1A1TDP1KMT2AMAPK1L3MBTL1 | |
| SCHEMBL9834113 | 0.92 | CYP1A2 (0.50) | ALDH1A1TDP1KMT2AMAPK1L3MBTL1 | |
| SCHEMBL7301662 | 0.92 | CYP1A2 (0.50) | ALDH1A1TDP1KMT2AMAPK1L3MBTL1 | |
| SCHEMBL24535020 | 0.90 | ALDH1A1 (0.50) | ALDH1A1TDP1KMT2AMAPK1L3MBTL1 | |
| SCHEMBL14191127 | 0.86 | ALDH1A1 (0.53) | ALDH1A1TDP1KMT2AMAPK1L3MBTL1 | |
| SCHEMBL12447238 | 0.86 | ALDH1A1 (0.53) | ALDH1A1TDP1KMT2AMAPK1L3MBTL1 | |
| SCHEMBL8847758 | 0.86 | ALDH1A1 (0.53) | ALDH1A1TDP1KMT2AMAPK1L3MBTL1 | |
| SCHEMBL20349700 | 0.83 | SLC1A1 (0.49) | ALDH1A1TDP1KMT2AMAPK1L3MBTL1 | |
| SCHEMBL28283813 | 0.83 | ALDH1A1 (0.53) | ALDH1A1TDP1KMT2AMAPK1L3MBTL1 | |
| SCHEMBL27426825 | 0.83 | SLC1A1 (0.49) | ALDH1A1TDP1KMT2AMAPK1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11999745-B2 | Pharmaceutical compounds | HEPTARES THERAPEUTICS LIMITED (GB) | 2024-06-04 | — | — | US | disclosed |
| US-11802122-B2 | 2-oxoimidazolidine-4-carboxamides as NAv1.8 inhibitors | MERCK SHARP & DOHME LLC (US) | 2023-10-31 | — | — | US | disclosed |
| EP-4263536-A1 | PHARMACEUTICAL COMPOUNDS | Heptares Therapeutics Limited (GB) | 2023-10-25 | — | — | EP | disclosed |
| US-20230312528-A1 | 2-OXO-IMIDAZOLIDINE-4-CARBOXAMIDES AS NAV1.8 INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2023-10-05 | — | — | US | disclosed |
| CN-116848109-A | Pharmaceutical compounds | 赫普泰雅治疗有限公司 | 2023-10-03 | — | — | CN | disclosed |
| CN-116134018-A | 2-oxoimidazolidine-4-carboxamide as NAV1.8 inhibitor | 默沙东有限责任公司 | 2023-05-16 | — | — | CN | disclosed |
| EP-4168393-A1 | 2-OXOIMIDAZOLIDINE-4-CARBOXAMIDES AS NAV1.8 INHIBITORS | Merck Sharp & Dohme LLC (US) | 2023-04-26 | — | — | EP | disclosed |
| US-20220380379-A1 | PHARMACEUTICAL COMPOUNDS | NXERA PHARMA UK LIMITED (GB) | 2022-12-01 | — | — | US | disclosed |
| WO-2022129951-A1 | PHARMACEUTICAL COMPOUNDS | HEPTARES THERAPEUTICS LIMITED (GB) | 2022-06-23 | — | — | WO | disclosed |
| WO-2022129951-A1 | PHARMACEUTICAL COMPOUNDS | HEPTARES THERAPEUTICS LIMITED (GB) | 2022-06-23 | — | — | WO | disclosed |
| US-20210403457-A1 | 2-OXOIMIDAZOLIDINE-4-CARBOXAMIDES AS NAV1.8 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2021-12-30 | — | — | US | disclosed |
| WO-2021257490-A1 | 2-OXOIMIDAZOLIDINE-4-CARBOXAMIDES AS NAV1.8 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2021-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210403457-A1 | 2-OXOIMIDAZOLIDINE-4-CARBOXAMIDES AS NAV1.8 INHIBITORS | SCN8A, TRPV1, SCN2A | ALDH1A1 1922/4885TDP1 4129/4885KMT2A 1962/4885 |
| US-11999745-B2 | Pharmaceutical compounds | CHRM1, CHRM2, CHRM4 | ALDH1A1 870/4885TDP1 2856/4885KMT2A 3532/4885 |
| US-20220380379-A1 | PHARMACEUTICAL COMPOUNDS | CHRM1, CHRM2, CHRM4 | ALDH1A1 870/4885TDP1 2856/4885KMT2A 3532/4885 |
| US-11802122-B2 | 2-oxoimidazolidine-4-carboxamides as NAv1.8 inhibitors | SCN8A, TRPV1, SCN2A | ALDH1A1 1922/4885TDP1 4129/4885KMT2A 1962/4885 |
| US-20230312528-A1 | 2-OXO-IMIDAZOLIDINE-4-CARBOXAMIDES AS NAV1.8 INHIBITORS | SCN8A, TRPV1, SCN2A | ALDH1A1 2181/4885TDP1 4038/4885KMT2A 1833/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.